Chris Gemmiti

Chris Gemmiti, Ph.D., is an accomplished cell and gene therapy executive with over 25 years of experience in both industry and academic settings. They have held leadership roles in the development and FDA approval of groundbreaking therapies, including CASGEVY, the first CRISPR gene-edited therapeutic, and GINTUIT™, the first allogeneic therapy. Chris has served as Vice President of Technical Operations at CRISPR Therapeutics, overseeing substantial teams and projects in gene editing and regenerative medicine. Currently, Chris is the SVP of Therapeutics Development at Cellino, continuing to advance innovations in the field. They earned a Ph.D. in Biomedical Engineering from Emory University and Georgia Tech, along with dual bachelor's degrees from The Johns Hopkins University.